Boston Scientific (BSX)
(Delayed Data from NYSE)
$68.49 USD
-0.13 (-0.19%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $68.49 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.49 USD
-0.13 (-0.19%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $68.49 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Boston Scientific (BSX) and Scivita Medical Expand Partnership
by Zacks Equity Research
Boston Scientific (BSX) and Scivita Medical announce an expanded strategic cooperation arrangement.
Abbott (ABT) Expands in Canada With First Eterna SCS Use
by Zacks Equity Research
Abbott's (ABT) Eterna SCS system reduces pain without causing discomfort. It leverages the BurstDR stimulation technology.
AHCO vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
AHCO vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific (BSX) Global Growth Robust, Macro Issues Ail
by Zacks Equity Research
Boston Scientific (BSX) is consistently registering fast recovery within its MedSurg segment in the post-pandemic period.
Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System
by Zacks Equity Research
Axonics' (AXNX) fourth-generation rechargeable Sacral Neuromodulation system will reduce the frequency of patient recharges significantly. The new form factor ensures ease of use.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Envista (NVST) Down 5.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Boston Scientific (BSX) Grows IC Business With New FDA Nod
by Zacks Equity Research
The AGENT DCB of Boston Scientific (BSX) is already available in Europe, parts of Asia Pacific and Latin America.
Why Is Boston Scientific (BSX) Up 2.1% Since Last Earnings Report?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Boston Scientific (BSX) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
C3.ai's (AI) Stock Is Soaring After Earnings But is it Time to Buy?
by Shaun Pruitt
As one of the more promising artificial intelligence companies, let's see if it's time to buy C3.ai's (AI) stock after revenue and contract growth fuel its post-earnings rally.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Boston Scientific Corporation (BSX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Boston Scientific (BSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Artivion (AORT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Artivion (AORT) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Boston Scientific (BSX) Surges 4.6%: Will the Rally Continue?
by Zacks Equity Research
Boston Scientific (BSX) is benefitting from an impressive gain in MedSurg market share and the strong adoption of WATCHMAN FLX.
Boston Scientific (BSX) Completes First Case With Its PFA System
by Zacks Equity Research
Boston Scientific (BSX) announces the completion of its first commercial cases with its FDA-cleared Farapulse PFA System in the United States.
Ecolab (ECL) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performance across the majority of its segments drives its fourth-quarter sales despite business challenges.
Prestige Consumer (PBH) Q3 Earnings Top, Gross Margin Expands
by Zacks Equity Research
Prestige Consumer's (PBH) third-quarter fiscal 2024 results reflect the power of a well-positioned and diversified portfolio.
Illumina (ILMN) Q4 Earnings Surpass Estimates, Margin Down
by Zacks Equity Research
Illumina (ILMN) Q4 revenues increase year over year, driven by NovaSeq X instrument and consumables sales.
Here's Why You Should Invest in Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) on strength across the target market and upbeat guidance.
Envista (NVST) Q4 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Strong performance in the Speciality Products & Technologies segment contributes to Envista's (NVST) Q4 revenues.
STERIS (STE) Q3 Earnings Top Estimates, Fiscal '24 Sales View Up
by Zacks Equity Research
STERIS' (STE) fiscal 2024 third-quarter results demonstrate the remarkable performance of the Healthcare segment.
Phibro (PAHC) Q2 Earnings and Revenues Top, Margins Down
by Zacks Equity Research
Phibro's (PAHC) fiscal 2024 second-quarter results reflect the strong performance of the Animal Health segment.
QIAGEN (QGEN) Q4 Earnings Miss, Operating Margin Expands
by Zacks Equity Research
QIAGEN's (QGEN) fourth-quarter performance reflects impressive CER sales growth and solid profitability.
Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year.